Pipeline of New Products

Products Currently in Development
Treatment/Use
Status of Product Development
Plasma Products
Human coagulation factor IX
Immune Globulin Intravenous (Human), Caprylate/Chromatography Purified and 20 nm virus filtration
Human Antithrombin III (concentration)
Human Cytomegalovirus Immunoglobulin
Human Fibrin Sealant
Human von Willebrand Factor
Prevention and control of bleeding in patients who suffer from hemophilia B.
Treatment for original immunoglobulin deficiency; secondary immunoglobulin deficiency and auto-immune deficiency diseases.
Treatment for (1) hereditary antithrombin III deficiency in connection with surgical or obstetrical procedures and (2) thromboembolism.
Prophylaxis and treatment of CMV infection, especially for the prevention of active virus replication for patients in immunosuppression, such as organ transplantation patients.
Adjunct to hemostasis on patients undergoing surgery in case that traditional surgical techniques (such as suture, ligature or cautery) are ineffective or impractical.
Treatment of bleeding episodes including surgical bleeding in patients with von Willebrand disease
Completed the clinical trial and submitted documentation for the registration purpose.
Obtained approval for clinical trial by the NMPA. Commenced clinical trial program.
Obtained approval for clinical trial by the NMPA. Commenced clinical trial program.
Obtained approval for clinical trial by the NMPA. Commenced clinical trial program.
Obtained approval for clinical trial by the NMPA.
Obtained approval for clinicaltrial by the NMPA.
4
3
3
3
3
3
Non-plasma products
Second generation artificial dura mater
Absorbable oral repair membrane
Bio-artificial membrane
Bio-artificial intraocular pressure maintenance membrane
Dura substitutes which are used when the patients’ dura cannot be sutured satisfactorily and watertight closure is difficult to achieve.
for oral and maxillofacial surgery
for repairing maxillofacial bone defect
for ophthalmic surgery
Completed the clinical trial and submitted documentation for the registration purpose.
Approaching completion of the supplementary clinical trial after previous submission of documentation for the registration purpose
Commenced clinical trial program.
Commenced clinical trial program.
4
3
3
3

Forward-Looking Statement

This page may include forward-looking statements made under the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable as of today, those statements are subject to risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

The company does not assume any obligation to update any forward-looking statements as a result of new information, future events, changes in market conditions or otherwise, except as required by law. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in China Biologic's 2019 Annual Report on Form 20-F and the company's other filings with the Securities and Exchange Commission (SEC) available at the SEC's Internet site (www.sec.gov).

No Duty to Update

The contained in this chart was current as of March 13, 2020. While this pipeline chart remains on the company's website the company assumes no duty to update the information to reflect subsequent developments. Consequently, investors should not rely upon the information as current or accurate after March 13, 2020.

The chart reflects China Biologic's pipeline of new products as of March 13, 2020.

© 2018 明陞体育m88APP-m88app-M88明陞 All Rights Reserved.           京ICP备18053264号